Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a exercise program when combined with rivastigmine (Exelon patch) drug treatment compared with rivastigmine drug treatment alone would improve quality of life, ability to perform activities of daily living (ADL) and cognition in patients with Alzheimer's disease.

Hypothesis:

Ho: Rivastigmine drug treatment combined with exercise is not superior to rivastigmine drug treatment to improve quality of life of Alzheimer's disease patients.

H1: Rivastigmine drug treatment combined with exercise is superior to rivastigmine drug treatment to improve quality of life of Alzheimer's disease patients, with an expectative of 15% of improvement in the quality of life scale measurement

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of Bahia
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

• Previous diagnosis of probable Alzheimer's disease

• At least 55 years of age

• Same caregiver (familiar or paid one) for at least 3 months before, who is able to follow the patient in a two-day/week exercise program

• Do not be taking other prescribed medication for Alzheimer disease

• Treated stable hypertension

Exclusion Criteria:

• Mini-Mental State Examination (MMSE) score of less than 12

• Can't follow simple commands;

• Can't answer two or more items of Quality of life questionnaire

• Practiced regular exercise or physiotherapy/ occupational therapy in the last two months.

• Diagnosed psychiatric condition (including depression).

• Use of neuroleptic drugs

• Orthopedic, neurologic, or behavioral limitations that may preclude exercise training

• Visual or hearing impairment that may preclude exercise training or comprehension